Prelude Therapeutics社は、サターラのGlobalSubmit eCTDソフトウェアを用いて承認申請の品質管理（QC）プロセスを数時間から数分へと短縮
2019年、小規模のがん創薬企業であるPrelude Therapeutics社は、電子共通技術文書（eCTD）提出のためにGlobalSubmit提出管理ソフトウェアを導入しました。Prelude Therapeuticsの薬事チームは非常にスリムで、年間30件以上の申請を担当しています。そのため、eCTDの発行、バリデーション基準のチェック、レビューには最大限の効率性が求められたのです。
The company found that their eCTD publishing process was not agile enough to meet their needs to implement updates quickly to submissions and provided limited reviewing capabilities through a third party. Without eCTD viewing software, they were unable to review the full scope of their submissions, hindering an effective review process. These challenges resulted in the decision to bring on GlobalSubmit eCTD software to make their regulatory submissions process more efficient.
Following the initial in-depth training provided by Certara, user acceptance testing (UAT) and validation, GlobalSubmit eCTD software was implemented into the regular review process. Hyperlinks and bookmarks are seamlessly created, and quality check (QC) is performed quickly and efficiently using the LINK and CROSSCHECK functionality in GlobalSubmit PUBLISH. With GlobalSubmit VALIDATE, more than 200 error conditions are checked, eliminating the risk of technical rejection. As a result, the QC process for each submission has been reduced from hours to minutes, saving their regulatory team considerable time.
For other stakeholders involved in the review process, GlobalSubmit WebReview provides a simple, easy-to-use interface to quickly search through applications and approve specific submission content. With GlobalSubmit eCTD software, the team appreciates that they can review the backbone of the regulatory submission, not just the folder structure, and that updates to eCTD requirements are automatically applied to the software and checked in real-time with live validation, eliminating the inefficiencies of finding technical issues. Since implementing GlobalSubmit eCTD software, Prelude Therapeutics has saved a considerable amount of time in their QC process and has become more efficient with their regulatory submissions.
